RESULTS ROUND-UP: Hologic on the up, Wright suffers from softness; Thoratec, Insulet
This article was originally published in Clinica
Executive Summary
Women’s health specialist Hologic said it has turned the corner, posting growth in all its key businesses in the fourth fiscal quarter ending 27 September. The firm’s Q4 revenue of $660.6m, up 6% from the same period last year, was helped by a 2% increase in Diagnostics revenue (at $297.1m), a 3% increase in Breast Health ($241.5m), a 2% increase in GYN Surgical ($78.5m) and a 10% increase Skeletal Health ($23.4m). Hologic’s largest franchise, Diagnostics, benefited from growth in its molecular diagnostics and blood screening lines, but this was partially offset by acontinuing decrease in US sales of its ThinPrep pap tests, which the company blamed on “interval expansion”.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.